China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis ...

Nasal irrigation can be a useful addition to the management of chronic upper respiratory conditions, including nasal ...

KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present for a minimum of 3 months.[1][1] Its true prevalence is difficult to ...

The presence and type of asthma is influenced by sensitization, and the duration and severity of allergic rhinitis. Nasal symptoms, airflow and markers of inflammation directly correlate with ...

Allergic rhinitis is the inflammation of nasal passageways that occurs when your immune system overreacts to allergens such as pollen, pet dander, or dust mites that are in the air. When it's ...

KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...

For some people, the classic symptoms of a sinus infection, including nasal congestion and discharge, are also accompanied by ...

Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...

placebo-controlled phase III study to confirm the efficacy and safety of Stapokibart injection in treatment of adult patients with seasonal allergic rhinitis who are poorly controlled with nasal ...